{"id":"NCT00742469","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Rifaximin for Prevention of Travellers' Diarrhea","officialTitle":"A Randomized,Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travellers' Diarrhea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2005-09","completion":"2007-04","firstPosted":"2008-08-27","resultsPosted":"2019-12-18","lastUpdate":"2019-12-18"},"enrollment":210,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Diarrhea"],"interventions":[{"type":"DRUG","name":"Rifaximin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.","primaryOutcome":{"measure":"Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment","timeFrame":"14 days","effectByArm":[{"arm":"Treatment Arm","deltaMin":15,"sd":null},{"arm":"Placebo Arm","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Mexico"]},"refs":{"pmids":["20412178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":106},"commonTop":["Diarrhea","Abdominal Pain","Defecation Urgency","Flatulence","Rectal tenesmus"]}}